{"entity":{"id":"geek-gene","kind":"company","name":"Geek Gene","aka":["Beijing Geekgene Technology Co., Ltd.","GeekGene"],"tldr":"Geek Gene grows a patient's own cancer-recognising T cells in the laboratory, using chemicals rather than genetic engineering to make them more numerous and longer-lived, and gives them back to treat advanced solid tumours.","summary":"Beijing Geekgene Technology Co., Ltd. (Geek Gene) develops autologous tumour-reactive T cell therapies using what it calls an AI-powered Cell Fate Navigation System, which combines single-cell analysis with non-genetic chemical reprogramming to expand T cells, reverse exhaustion and enrich for tumour-reactive clones. Its lead product GK01 is an autologous tumour-reactive T cell product; the company announced in November 2025 that China's NMPA Center for Drug Evaluation had cleared an IND for GK01. GK02 is a related product made from T cells taken from malignant ascites. The company sponsors early-phase registry studies of GK01 in advanced solid tumours and advanced lung cancer (NCT07412665, NCT07414316, NCT07482319, NCT07673419) and of GK02 in malignant ascites (NCT07378436). Its first registered cancer trial, NCT06431100, a single-centre study of GK01 in gastric, oesophageal and cervical cancer, non-small cell lung cancer and triple-negative breast cancer, was posted on ClinicalTrials.gov in May 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.geekgene.cn/"},{"label":"Technology page","url":"https://www.geekgene.cn/technology.html"},{"label":"ClinicalTrials.gov: first study of GK01 tumour-reactive T cells (NCT06431100)","url":"https://clinicaltrials.gov/study/NCT06431100"},{"label":"ClinicalTrials.gov: phase 1 trial of GK01 in advanced solid tumours (NCT07482319)","url":"https://clinicaltrials.gov/study/NCT07482319"},{"label":"ClinicalTrials.gov: early phase 1 trial of GK02 in malignant ascites (NCT07378436)","url":"https://clinicaltrials.gov/study/NCT07378436"}],"tags":[],"related":[],"cancers":["gastric","esophageal","cervical","nsclc","tnbc"],"sections":["cell-therapy","immunotherapy"],"technologies":["til-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website read on 29 October 2026; it gives a Beijing (010) telephone number but no street address, so the Beijing headquarters rests on the registered company name. Founding year not stated on the company website. No financing round is recorded because none is described on the site. The registry entry for NCT06431100 labels the intervention 'TCR T-cells', but the trial title and the company describe non-engineered autologous tumour-reactive T cells; the TIL therapy technology tag is the closest available and should be read loosely. Trial facts from ClinicalTrials.gov records read on 29 October 2026."],"hq":"Beijing","country":"CN","companyType":"cell-therapy","website":"https://www.geekgene.cn/","stage":"startup","investors":[],"funding":[]},"route":"/companies/geek-gene/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}]}}